Genetic testing plays a powerful role in prostate cancer care. It can identify inherited mutations—such as BRCA1 and BRCA2—that may increase cancer risk and guide both treatment decisions and screening for family members. This approach also supports cascade testing, where sons, brothers, and close relatives are offered genetic testing once a mutation is identified, helping families catch cancers earlier. In this short excerpt, Dr. Kristen Scarpato, MD, MPH, Associate Professor of Urology and Uro

針對BRCA突變乳癌患者 PARP抑制劑納入健保輔助治療選項